Emraclidine EMPOWER data now expected second half 2024
Darigabat ADAPT trial in panic disorder initiated
Cash, cash equivalents, and marketable securities of $825.1 million as of June 30, 2023, expected to support a data-rich 2024 and fund operations into 2025
Conference call today at 8:00 a.m. ET
Cerevel will host a conference call and webcast today, August 2, at 8:00 a.m. ET to discuss its second quarter 2023 financial results and key pipeline and business updates. To access the call, please register at this link. Once registered, you will receive the dial-in information and a unique PIN number.
A live webcast of the call, along with supporting slides, will be available on the investors section of Cerevel’s website at investors.cerevel.com. Following the live webcast, an archived version of the call will be available on the website.
https://finance.yahoo.com/news/cerevel-therapeutics-reports-second-quarter-103000270.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.